Site notifications

Sub menu

 

 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset for information on the evaluation of prescription medicines.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

Topics

AusPAR Date

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

1125 result(s) found, displaying 601 to 625

  • AusPAR: Golimumab (rmc)

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Golimumab (rmc)

  • AusPAR: Ephedrine Hydrochloride

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Ephedrine Hydrochloride

  • AusPAR: Oxycodone / Naloxone

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Oxycodone / Naloxone

  • AusPAR: Diltiazem hydrochloride

    Australian public assessment report (AusPar)
    Australian public assessment report for Diltiazem hydrochloride

  • AusPAR: Progesterone

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Progesterone

  • AusPAR: Methotrexate

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Methotrexate

  • AusPAR: Ticagrelor

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Ticagrelor

  • AusPAR: Grazoprevir / Elbasvir

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Grazoprevir / Elbasvir

  • AusPAR: Nitric oxide

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Nitric oxide

  • AusPAR: Albumin (human)

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Albumin (human)

  • AusPAR: Bevacizumab (rch)

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Bevacizumab (rch)

  • AusPAR: Ixekizumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Ixekizumab

  • AusPAR: Daclizumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Daclizumab

  • AusPAR: Deoxycholic acid

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Deoxycholic acid

  • AusPAR: Adalimumab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Adalimumab

  • AusPAR: Brivaracetam

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Brivaracetam

  • AusPAR: Mepolizumab (rch)

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for mepolizumab (rch)

  • AusPAR: Forxiga

    Australian public assessment report (AusPar)
    Forxiga (dapagliflozin) was approved as an adjunct to diet and exercise in patients with type 2 diabetes mellitus for whom metformin is otherwise indicated but not tolerated. It was also approved as a combination therapy to be used with other drugs to improve glycaemic control.

  • AusPAR: Ipilimumab (rch)

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Ipilimumab (rch)

  • AusPAR: Rituximab

    Australian public assessment report (AusPar)
    Australian Public Assessment Report for Rituximab